Researcher find potential target for atherosclerosis
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Obesity: Arecor Therapeutics partners with TRx Biosciences
/in News/by Thomas GabrielczykBritish companies Arecor Therapeutics plc and TRx Biosciences Ltd combine their technologies to formulate an oral GLP-1 receptor agonist with enhanced bioavailability<br />
Scientist create non-digestible aptamer
/in News/by Thomas GabrielczykGerman researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
Scientists create non-digestible aptamer
/in News/by Thomas GabrielczykGerman researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
SynaptixBio Ltd gets FDA ODD for leukodystrophy
/in News/by Thomas GabrielczykRare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
/in News/by Thomas GabrielczykPierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Bayer SE secures rights to in €310m deal
/in News/by Thomas GabrielczykBayer AG has purchased European commercialisation rights for the transthyretin amyloid cardiomyopathy candidate acoramidis from BridgeBio Inc.<i> </i>
Swiss vaccine developer Limma Tech get CARB-X grant
/in News/by Thomas GabrielczykSwiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Curve Therapeutics raises £40.5m in Series A financing
/in News/by Thomas GabrielczykIntracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
Pacifico Biolabs raises US$3.3m in pre-seed round
/in News/by Thomas GabrielczykGerman foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.<br /><br /><br /><br />